Patents Assigned to Research Corporation Technologies, Inc.
  • Patent number: 5759389
    Abstract: The present invention relates to various methods, such as an above-ground method and an in-ground method, of using a palladized iron bimetallic system for the dechlorination of chlorinated organic compounds from effluents containing the same. The use of palladized iron bimetallic system results in the dechlorination of the chlorinated organic compound into environmentally safe reaction products. The present invention also provides kits, devices, and other instruments that use the above-mentioned palladized iron bimetallic system for the dechlorination of chlorinated organic compounds.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: June 2, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Quintus Fernando, Rosy Muftikian, Nic Korte
  • Patent number: 5759535
    Abstract: The present invention is directed to a method for the treatment of neoplastic disease comprising administering to a mammal having a tumor a cellular immunogen comprising an allogeneic population of cells expressing S one or more cytoldnes and tumor associated antigens encoded by autologous genomic tumor DNA.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: June 2, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Edward P. Cohen
  • Patent number: 5760027
    Abstract: The present invention relates to the use of 7-alkylidene derivatives of cephalosporin esters, such as sulfides, sulfoxides, and sulfones, as inhibitors of human leukocyte elastase. These materials are therefore useful as anti-inflammatory and anti-degenerative agents.
    Type: Grant
    Filed: December 6, 1996
    Date of Patent: June 2, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, Akireddy Srinivasa Rao, Greg C. Adam
  • Patent number: 5753780
    Abstract: Disclosed are polymers comprising phenyl rings pendant from the polymer chains or incorporated therein, wherein the phenyl rings are substituted with aldehyde and/or carboxylic acid functionalities and/or derivatives thereof. Also disclosed is a catalytic oxidation process for producing such polymers from precursor polymers containing benzylic carbon atoms.
    Type: Grant
    Filed: August 16, 1995
    Date of Patent: May 19, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Harald D. H. Stover, Pei Li, Lorenzo Ferrari, Robert T. Shaver, Djordje (George) Vlaovic
  • Patent number: 5750767
    Abstract: The present invention is directed to the process of preparing a peptide comprising reacting a first amino acid or peptide with an amino acid fluoride of the formula: ##STR1## or the acid fluoride salts thereof wherein BLK is an N-amino protecting groupAA is an amino acid residue andX is H or a protecting group useful,and the first amino and peptide have a free amino group and a blocked carboxy end.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 12, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Louis A. Carpino, Ayman Ahmed El-Faham
  • Patent number: 5744462
    Abstract: Compounds of the formulae: ##STR1## useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agent.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 28, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Arthur G. Schwartz, Marvin Louis Lewbart
  • Patent number: 5741486
    Abstract: The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment the sequence that is desired to be deleted is the retroviral cis-acting encapsidation sequence (E) essential for virus production in helper cells. In gene therapy embodiments, the E sequence is deleted upon reverse transcription in target cells, thus preventing spread of retroviral vectors to non-target cells in the event of infection with replication competent viruses. The retroviral vectors of the present invention thus provide safe vectors for gene therapy.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 21, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Vinay K. Pathak, Wei-Shau Hu
  • Patent number: 5728522
    Abstract: The present invention is directed to a rapid and sensitive method for detecting Ureaplasma urealyticum using U. urealyticum-specific probes and oligonucleotides. In particular a target sequence can be amplified by in vitro nucleic acid amplification techniques or directly detected by nucleic acid hybridization using the subject probes and oligonucleotides. U. urealyticum-specific nucleic acids which do not recognize or hybridize to genomic nucleic acid of Mycoplasma species are also provided.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: March 17, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Vito G. Del Vecchio, Louis E. Blouse, Jr., Ferne K. McCleskey
  • Patent number: 5728804
    Abstract: A method for renaturing a denatured protein is provided comprising contacting a solution or suspension of said denatured protein in a detergent-free liquid medium with an amount of a cyclodextrin effective to renature said protein, and optionally, recovering the renatured protein in essentially pure form.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 17, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Ajit Sharma, Nadarajah Karuppiah
  • Patent number: 5725854
    Abstract: The present invention describes a method of treating a disease that results from a deficiency of a biological factor which includes administering to a mammal Sertoli cells and cells that produce the biological factor. In particular, the present invention describes a method of treating diabetes mellitus by transplanting pancreatic islet of Langerhans cells in conjunction with Sertoli cells to create an immunologically privileged site. A method of creating an immunologically privileged site in a mammal for cellular transplants is further described by the present invention. A pharmaceutical composition comprising Sertoli cells and cells that produce a biological factor is also provided.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: March 10, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Helena P. Selawry
  • Patent number: 5726282
    Abstract: A class of rigid rod and latter polymers having light emitting capability is provided. Included in this class of polymers are those having novel repeating structural units. These rigid rod and ladder polymers are employed in light emitting diodes.
    Type: Grant
    Filed: June 19, 1996
    Date of Patent: March 10, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Samson A. Jenekhe, John A. Osaheni
  • Patent number: 5723314
    Abstract: A method is described for diagnosing rheumatoid arthritis by providing a recombinant antigen (RAMA) and detecting rheumatoid arthritis-associated IgM antibodies against the RAMA antigen in patient sera. The RAMA antigen comprises SEQ ID NO:3 and peptides substantially homologous thereto. A purified and isolated DNA encoding the RAMA antigen and a transformed host containing the DNA are also disclosed.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: March 3, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Ramesh K. Prakash
  • Patent number: 5716705
    Abstract: A protective monolayer is formed on e.g. silica gel and glass surfaces comprising a monolayer of silicon and oxygen atoms which is substituted with first and second hydrocarbyl substituents.
    Type: Grant
    Filed: October 31, 1996
    Date of Patent: February 10, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Mary J. Wirth, Hafeez O. Fatunmbi
  • Patent number: 5714481
    Abstract: Steroids of the formula: ##STR1## useful as cancer preventive agents, anti-obesity agents, anti-hyperglycemic agents, anti-aging agents, and anti-hypercholesterolemic agents and anti-auto-immune agents.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: February 3, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Arthur G. Schwartz, John R. Williams, Magid Abou-Gharbia, Daniel Swern, deceased, Marvin Louis Lewbart
  • Patent number: 5714353
    Abstract: The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment the sequence that is desired to be deleted is the retroviral cis-acting encapsidation sequence (E) essential for virus production in helper cells. In gene therapy embodiments, the E sequence is deleted upon reverse transcription in target cells, thus preventing spread of retroviral vectors to non-target cells in the event of infection with replication competent viruses. The retroviral vectors of the present invention thus provide safe vectors for gene therapy.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: February 3, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Vinay K. Pathak, Wei-Shau Hu
  • Patent number: 5712418
    Abstract: The present invention is directed to the process of preparing a peptide comprising reacting a first amino acid or peptide with an amino acid fluoride of the formula: ##STR1## or the acid fluoride salts thereof wherein BLK is an N-amino protecting groupAA is an amino acid residue andX is H or a protecting group useful,and the first amino and peptide have a free amino group and a blocked carboxy end.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: January 27, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Louis A. Carpino, Ayman Ahmed El-Faham
  • Patent number: 5712084
    Abstract: The present invention contemplates a methodology which employs cold perfusion of donor organs with a colloid preservation solution at a selected perfusion pressure which avoids tubular reabsorption and consequent energy loss. The present invention is also directed towards the direct continuous measurement of Glomerular Filtration Rate (GFR) through measurement of urine formation during the perfusion period. The present invention further provides a method to assess afferent arteriole and efferent arteriole vascular patency. The present invention further contemplates the maintenance of tubular patency during perfusion. The present invention is also directed to a method for monitoring cold ischemia damage as an indication for timing and dosage of nephrotoxic immunosuppressant agents, e.g., Cyclosporin A. The present invention still further contemplates a device for performing the test of the present invention.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: January 27, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Richard W. Osgood
  • Patent number: 5707828
    Abstract: The present invention is directed to expression cassettes comprising a 5' regulatory region from at least one of the Pichia pastoris AOXI gene, p40 gene, DASI gene or HIS4 gene, operably linked to an HSA structural gene including the HSA signal sequence. The HSA structural gene has a translational start codon within 0 to 11 deoxyribonucleotides from the 5' end of the HSA structural gene and is operably linked to a 3' termination sequence. Further, the adenine and thymine content of the intervening deoxyribonucleotides is in the range from about 55 to about 64%. The expression cassette may be an autonomously replicating vector or an integrative vector. Other embodiments of the present invention include Pichia pastoris strains transformed with the HSA expression cassettes and processes for secretion of HSA using the expression cassettes.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Kotikanyadan Sreekrishna, Juerg F. Tschopp, Gregory P. Thill, Russell A. Brierley, Kathryn A. Barr
  • Patent number: 5707629
    Abstract: The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus are major targets of the immune response to herpesviral infection. Hence, an important aspect of this invention is directed towards a vaccine against EHV-1 and treatment of EHV-1 infection by anti-EHV-gD antibodies or antisera.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Dennis J. O'Callaghan
  • Patent number: 5708518
    Abstract: A method of and system for rendering a halftone image of a gray scale image by utilizing a pixel-by-pixel comparison of the gray scale image against a blue noise mask is disclosed in which the gray scale image is scanned on a pixel-by-pixel basis and compared on a pixel-by-pixel basis to an array of corresponding data points contained in a blue noise mask stored in a PROM or computer memory in order to produce the desired halftoned image. Both digital and optically implemented halftone methods are disclosed. Application specific modifications of the blue noise mask as well as its use for producing halftoned color images are also disclosed.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Kevin J. Parker, Theophano Mitsa